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Introduction {#acn3399-sec-0005}
============

Ischemic stroke is a major cause of morbidity and mortality worldwide.[1](#acn3399-bib-0001){ref-type="ref"}, [2](#acn3399-bib-0002){ref-type="ref"} Currently, the only approved treatments for acute ischemic stroke include thrombolysis and endovascular thrombectomy.[3](#acn3399-bib-0003){ref-type="ref"} Because of the stringent time criteria to qualify for these treatments,[4](#acn3399-bib-0004){ref-type="ref"} \<7% of all ischemic stroke patients actually receive these reperfusion interventions.[5](#acn3399-bib-0005){ref-type="ref"}, [6](#acn3399-bib-0006){ref-type="ref"}, [7](#acn3399-bib-0007){ref-type="ref"} Unfortunately, no other neuroprotective agent has been demonstrated to improve outcome. Thus, the development of a pharmacological intervention that mitigates secondary neuronal injury remains a compelling unmet clinical need.

The postischemic brain demonstrates a proinflammatory cascade, characterized by glial activation and release inflammatory mediators, neuronal excitotoxicity, and oxidative stress.[8](#acn3399-bib-0008){ref-type="ref"}, [9](#acn3399-bib-0009){ref-type="ref"} This neuroinflammatory cascade begins immediately after vascular occlusion and exacerbates secondary neuronal injury, resulting in further tissue injury days after the initial insult.[9](#acn3399-bib-0009){ref-type="ref"}, [10](#acn3399-bib-0010){ref-type="ref"}, [11](#acn3399-bib-0011){ref-type="ref"}, [12](#acn3399-bib-0012){ref-type="ref"} Targeting this cascade has potential for reducing tissue injury and lengthening the therapeutic window for revascularization. However, drugs targeting the inflammatory cascade have been unsuccessful in clinical trials, notably due to adverse effects and poor central nervous system (CNS) penetration.[13](#acn3399-bib-0013){ref-type="ref"}, [14](#acn3399-bib-0014){ref-type="ref"}

Apolipoprotein E (apoE) is the primary apolipoprotein produced in the CNS, where its glial secretion is upregulated after injury.[15](#acn3399-bib-0015){ref-type="ref"} ApoE has demonstrated to suppress microglial and astrocyte activation in in vitro[16](#acn3399-bib-0016){ref-type="ref"}, [17](#acn3399-bib-0017){ref-type="ref"}, [18](#acn3399-bib-0018){ref-type="ref"} and in vivo models of brain injury.[19](#acn3399-bib-0019){ref-type="ref"}, [20](#acn3399-bib-0020){ref-type="ref"} In addition to its immunomodulatory effects, apoE attenuates N‐methyl‐D‐aspartate‐mediated neuronal excitotoxicity in cell culture models.[21](#acn3399-bib-0021){ref-type="ref"} ApoE also appears to protect from cerebral ischemia as apoE‐deficient animals demonstrate worse outcomes, both functionally and histologically, following experimental ischemia.[19](#acn3399-bib-0019){ref-type="ref"}, [22](#acn3399-bib-0022){ref-type="ref"}, [23](#acn3399-bib-0023){ref-type="ref"} ApoE exists in humans as three common isoforms, differing by single amino acid substitutions at residues 112 and 158.[24](#acn3399-bib-0024){ref-type="ref"} Isoform‐specific protective effects on endogenous neuroinflammatory responses have been observed in humans across different acute brain injuries[25](#acn3399-bib-0025){ref-type="ref"}, [26](#acn3399-bib-0026){ref-type="ref"} but not in cerebral ischemia.[27](#acn3399-bib-0027){ref-type="ref"}, [28](#acn3399-bib-0028){ref-type="ref"} Due to its large size, apoE does not cross the blood--brain barrier (BBB) and its therapeutic potential is limited. To overcome this limitation, smaller apoE‐mimetic peptides, derived from the helical receptor binding region of apoE, have been developed that retain the functional effects of the holoprotein on receptor binding[29](#acn3399-bib-0029){ref-type="ref"} in reducing inflammation[17](#acn3399-bib-0017){ref-type="ref"} and neuronal excitotoxicity.[30](#acn3399-bib-0030){ref-type="ref"} Moreover, these apoE‐mimetic compounds have demonstrated long‐term functional and histological improvements in preclinical models of ischemic stroke[31](#acn3399-bib-0031){ref-type="ref"}, [32](#acn3399-bib-0032){ref-type="ref"} and numerous other acute CNS injuries[33](#acn3399-bib-0033){ref-type="ref"}, [34](#acn3399-bib-0034){ref-type="ref"}, [35](#acn3399-bib-0035){ref-type="ref"}, [36](#acn3399-bib-0036){ref-type="ref"}, [37](#acn3399-bib-0037){ref-type="ref"}, [38](#acn3399-bib-0038){ref-type="ref"}, [39](#acn3399-bib-0039){ref-type="ref"}, [40](#acn3399-bib-0040){ref-type="ref"}, [41](#acn3399-bib-0041){ref-type="ref"}, [42](#acn3399-bib-0042){ref-type="ref"}, [43](#acn3399-bib-0043){ref-type="ref"}, [44](#acn3399-bib-0044){ref-type="ref"}, [45](#acn3399-bib-0045){ref-type="ref"}, [46](#acn3399-bib-0046){ref-type="ref"} (Table [1](#acn3399-tbl-0001){ref-type="table-wrap"}).

###### 

Therapeutic efficacy of apoE‐mimetic peptides in preclinical models of acute brain injuries

  Injury                                                Species                ApoE‐mimetic peptide                                                                     Functional improvement and survival advantage                                   Histological improvement                                                     Biochemical improvement                                                        References
  ----------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------
  Ischemic Stroke (tMCAO)                               Sprague--Dawley rats   COG1410                                                                                  Improved vestibulomotor (7 days), locomotor function                            Reduction in infarct volume (35 days)                                        --                                                                             Tukhouvskaya et al., 2009
  C57Bl/6J mice                                         COG1410                Improved vestibulomotor function (3 days)                                                Reduction in infarct volume (24 h), cerebral edema                              Reduced of inflammatory cytokine (TNF‐*α* RNA)                               Wang et al., 2013                                                              
  Perinatal Hypoxia‐Ischemia                            Wistar rat pups        COG133                                                                                   Reduced mortality                                                               Reduction in brain tissue loss                                               --                                                                             McAdoo et al., 2005
  Intracerebral hemorrhage (collagenase injection)      C57Bl/6J mice          COG1410                                                                                  Improved vestibulomotor function (7 days)                                       Reduction in cerebral edema                                                  Reduction in inflammatory cytokines (IL‐6 and eNOS)                            James et al., 2009
  C57/BL6 mice                                          COG1410                Improved vestibulomotor function (5 days), survival and reduced neurological severity.   Reduction in microgliosis, cerebral edema, and neuronal injury                  Reduction in inflammatory signaling (phosphorylated p38 and NF‐kB protein)   Laskowitz et al., 2012                                                         
  C57/BL6 mice                                          CN‐105                 Improved vestibulomotor function (5 days) and memory                                     Reduction in cerebral edema, microgliosis, and neuronal degeneration            --                                                                           Lei et al., 2016                                                               
  Subarachnoid hemorrhage                               C57/BL6 mice           COG1410                                                                                  Improved vestibulomotor function and reduced neurological severity              Reduction in microgliosis                                                    Reduction in apoptotic markers and inflammatory signals (JNK, c‐Jun and p65)   Wu et al., 2016
  C57/BL6 mice                                          COG1410                Improved vestibulomotor function (3 days), survival and reduced neurological severity    Reduction in vasospasm and cerebral edema                                       --                                                                           Gao et al., 2006                                                               
  C57/BL6 mice                                          COG1410                Improved vestibulomotor function (3 days)                                                Reduction in vasospasm                                                                                                                                       Mesis et al., 2006                                                             
  Traumatic brain injury (closed head injury)           C57Bl/6J mice          COG133                                                                                   Improved vestibulomotor function and memory (5 days)                            Reduction in neuronal degeneration                                           Reduction in oxidative stress (aconitase) and inflammatory cytokine (TNF*α*)   Lynch et al., 2005
  C57Bl/6J mice                                         COG133                 Improved vestibulomotor function (5 days)                                                Reduction in neuronal degeneration and microgliosis                             Reduction in amyloid‐beta expression                                         Wang et al., 2007                                                              
  C57Bl/6J mice                                         COG1410                Improved vestibulomotor function (5 days) and memory                                     Reduction in neuronal degeneration and microgliosis                             --                                                                           Laskowitz et al., 2007                                                         
  Traumatic brain injury (controlled cortical impact)   Sprague--Dawley rats   COG1410                                                                                  Improved sensorimotor function (14 days)                                        Reduction in lesion volume and astrocytosis                                  --                                                                             Hoane et al., 2007
  Sprague--Dawley rats                                  COG1410                Improved somatosensory function and memory                                               Reduction in neuronal degeneration                                              --                                                                           Hoane et al., 2009                                                             
  C57Bl/6J mice                                         COG1410                Improved vestibulomotor (3 days) and neurological function                               Reduction in lesion volume, cerebral edema, and BBB disruption                  --                                                                           Cao et al., 2016                                                               
  C57Bl/6J mice                                         COG1410                Improved vestibulomotor function (7 days)                                                Reduction in cerebral edema, microvascular density, and neuronal degeneration   Reduction in VEGF expression and increased brain glucose uptake              Qin et al., 2016                                                               

BBB, blood--brain barrier; eNOS, endothelial nitric oxide synthase; IL‐6, interleukin‐6; JNK, c‐Jun N‐terminal kinases; NF‐kB, nuclear factor kappa‐light‐chain‐enhancer of activated B cells; tMCAO, transient middle cerebral artery occlusion; TNF‐*α*, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.
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CN‐105 is an apoE‐mimetic 5 amino acid peptide (acetyl‐Valine‐Serine‐Arginine‐Arginine‐Arginine‐amide) derived from the apoE receptor binding region by linearizing the polar face of the amphipathic helix involved in receptor interaction.[35](#acn3399-bib-0035){ref-type="ref"} CN‐105 has the advantage of increased CNS penetration[35](#acn3399-bib-0035){ref-type="ref"} over previous larger apoE‐mimetic peptides and has demonstrated efficacy in experimental intracerebral hemorrhage.[35](#acn3399-bib-0035){ref-type="ref"} Based on its preclinical safety and efficacy, CN‐105 was granted a successful investigational new drug application by the United States Food and Drug Administration and recently completed a Phase 1 clinical trial (clinical trials identifier: NCT02670824), where safety was demonstrated in both single escalating dose and multiple dosing paradigms.[47](#acn3399-bib-0047){ref-type="ref"} The evidence of good CNS penetration, efficacy in acute brain injury models, and reassuring safety profile suggest CN‐105 may be a viable candidate drug for further clinical development as a neuroprotective agent.

This study evaluates the therapeutic efficacy of CN‐105 in a murine model of transient focal cerebral ischemia and reperfusion. We test the hypothesis that intravenous administration of CN‐105 reduces mortality, results in improvement of functional and histological outcomes after experimental ischemic stroke, and reduces microglial activation. We also explore the mechanisms by which CN‐105 exerts its immunomodulatory and neuroprotective effects by performing a phosphoproteomic analysis in animals exposed to cerebral ischemia.

Materials and Methods {#acn3399-sec-0006}
=====================

Physiological effects of CN‐105 {#acn3399-sec-0007}
-------------------------------

We performed a series of experiments to assess the safety and determine the physiological effects of CN‐105 using both males and females 8‐week‐old Crl:CD(SD) rats (Charles River Laboratories, Portage, Michigan). These experiments were independently conducted (MPI Research Inc, Mattawan, Michigan) prior to the conduct of further experiments in this study. These animals received an implanted femoral vein catheter exteriorized between the scapulae for intravenous dosing purposes. 0.9% Sodium Chloride for injection was used as vehicle. CN‐105 was synthesized by Polypeptide Inc (San Diego, CA) to a purity of \>99%. CN‐105 was dissolved in vehicle to the concentration of 1.25 mg/mL. Repeated intravenous administration of 5 mg CN‐105/kg/dose or vehicle, four times per day (20 mg/kg/day) for 14 days 6 h apart (total of 56 doses per animal). Compared to the subsequent experiments, doses of CN‐105 used in these physiological studies were 50 times higher per dose and 200 times higher per day. Animals were randomized prior to any experiments and outcome assessments were performed in a blinded fashion.

Multiple physiological parameters were measured in these experiments. These included body temperature, hematological (platelet count and coagulation profile), biochemistry (glucose, creatinine, and total bilirubin), and respiratory (respiratory rate and minute ventilation) evaluations. Full experimental details are available in Data [S1](#acn3399-sup-0001){ref-type="supplementary-material"}.

Peptide synthesis and administration {#acn3399-sec-0008}
------------------------------------

CN‐105 used in subsequent animal experiments was similarly synthesized by Polypeptide Inc (San Diego, CA) to a purity of \>99%. However, CN‐105 was dissolved in 1× phosphate‐buffered saline (PBS), reconstituted to 0.1 mg/kg concentration in 100 *μ*L volume and administered via tail vein injection.

Animal procedures {#acn3399-sec-0009}
-----------------

In all experiments, mice were randomized to treatment and vehicle group before injury and all animals were treated with allocation concealment. In each experiment, mice were randomized to treatment or vehicle groups prior to injury. Animals were treated with blinded concealment. All procedures and assessments were performed in blinded fashion. Animal procedures were approved by the Duke University Institutional Animal Care and Use Committee in keeping with established guidelines.

Model of focal ischemia and reperfusion {#acn3399-sec-0010}
---------------------------------------

Ten‐ to 13‐week‐old C57Bl/6J male mice (Jackson Laboratories, Bar Harbor, ME) were used. Focal cerebral ischemia was induced by filamentous transient middle cerebral artery occlusion (tMCAO), as previously described.[32](#acn3399-bib-0032){ref-type="ref"} To model the effect of CN‐105 in different clinical stroke severities, two different ischemic intervals were used. A 30‐min ischemic occlusion associated with high mortality was used to assess for mortality advantage and the phosphoproteomic signature of CN‐105 effects on large stroke volumes. A shorter 15‐min ischemic occlusion time, associated with lower mortality, was used to assess long‐term functional and histological endpoints.

### Functional assessments {#acn3399-sec-0011}

Vestibulomotor performance was assessed daily postinjury with the accelerating rotarod (Med Associates Inc, Georgia, Vermont), as previously described.[32](#acn3399-bib-0032){ref-type="ref"} The time in which the mouse was able to stay on the rotating rod before falling (rotarod latency) was recorded up to 300 sec and the average of three trials was used.

Motor coordination and limb muscle strength was assessed with the 4‐limb wire hanging test.[48](#acn3399-bib-0048){ref-type="ref"} A mouse was placed on the center of a wire grid upright and the grid was inverted gently. The time it took for the mouse to fall off the grid (hanging latency) was recorded up to 600 sec. The test was performed at 2 and 7 days post injury and repeated three times per day. Maximal hanging latency was used.

### Infarct volume measurements {#acn3399-sec-0012}

Coronally sectioned (1‐mm thick) brain slices were stained in 2% 2,3,5‐triphenyletrazolium chloride (Sigma, St. Louis, MO) according to protocol.[49](#acn3399-bib-0049){ref-type="ref"} After staining, images were captured and analyzed using open‐source software (Image J, version 1.49, National Institutes of Health, Bethesda, Maryland). The infarcted area per slice was determined by subtracting the area of viable stained tissue of the ipsilateral hemisphere from the unaffected viable area of the contralateral hemisphere. Final infarct volume was the sum of infarcted areas multiplied by slice thickness.

### Contralateral hemisphere microglial quantification {#acn3399-sec-0013}

Frozen coronal brain sections (40 *μ*m thick) were stained with anti‐rat F4/80 antibody (rat monoclonal, 1:10,000; Serotec, Raleigh, NC) specific for activated microglia and cells of the monocyte lineage.[34](#acn3399-bib-0034){ref-type="ref"} Microglial count was performed in the contralateral hippocampus using the optical fractionator method.[50](#acn3399-bib-0050){ref-type="ref"} Microglia per unit volume (count density) was used to allow comparability between animals.

TNF‐*α* suppression by CN‐105 in microglial cells {#acn3399-sec-0014}
-------------------------------------------------

For all in vitro experiments, C8‐B4 mouse microglia cells (ATCC, Manassas, VA) were used. We investigated the change in production of tumor necrosis factor‐alpha (TNF‐*α*) produced by increasing concentrations of CN‐105 (0.1, 0.3, and 1 *μ*M/mL) using fixed lipopolysaccharide (LPS) (Sigma‐Aldrich, St. Louis, MO) stimulation (10 ng/mL), and by fixed concentration of 1 *μ*M/mL of CN‐105 using increasing concentrations of LPS stimulation (10, 50, and 100 ng/mL). Cell supernatant was analyzed using Mouse TNF‐*α* DuoSet ELISA kit (R&D Systems, Minneapolis, MN) per manufacturer\'s protocol. All experiments were repeated six times and mean TNF‐*α* concentrations were recorded at 4 h post incubation.

Differential phosphopeptide expression {#acn3399-sec-0015}
--------------------------------------

Following 30 min of ischemia, CN‐105 or vehicle was administered at 15 min after reperfusion. At 30 min after reperfusion, mice were killed, brains were removed and dissected in the midsagittal plane. Each hemisphere was flash‐frozen separately in liquid nitrogen and stored at −80°C. The injured right hemispheres were used for analysis. Peptides were prepared from brain samples for liquid chromatography--tandem mass spectrometry (LC‐MS/MS) analysis (Data [S2](#acn3399-sup-0002){ref-type="supplementary-material"}). Peptide digests obtained from each of the samples were analyzed in a label‐free quantitative fashion using a nanoAcquity UPLC system coupled to a Synapt HDMS mass spectrometer (Waters Corp, Milford, MA) for unenriched peptide analyses and an LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, MA) for phosphopeptide analyses. Robust peak detection and label‐free alignment of individual peptides across all sample injections was performed using the commercial package Rosetta Elucidator v3.3 (Rosetta Biosoftware, Inc., Seattle, WA) with PeakTeller algorithm.

Statistical analysis {#acn3399-sec-0016}
--------------------

Independent two‐tailed *t*‐test was performed for infarct volume, microglial density analysis, and TNF‐*α* concentration of microglial cells. Repeated measures analysis of variance (ANOVA) was performed for rotarod and 4‐limb wire hanging latencies, and Dunnett\'s post hoc test for multiple comparisons was used. Log‐rank test was performed for survival evaluation. Principal components analysis was performed between sample groups to screen for outliers in the phosphoproteomic data. The independent two‐tailed *t*‐test was performed on log[2](#acn3399-bib-0002){ref-type="ref"} protein intensities of the phosphopeptide (peptide‐level) datasets. Significance level for all tests was set at *P* \< 0.05. All data were analyzed using SPSS version 20 (IBM, Armonk, NY).

Results {#acn3399-sec-0017}
=======

Absence of adverse physiological effects by CN‐105 {#acn3399-sec-0018}
--------------------------------------------------

Repeated intravenous administration of 5 mg CN‐105/kg/dose 4× per day (20 mg/kg/day) for 14 days over 5 min did not produce mortality and was without significant clinical effect on body temperature, hematology and coagulation, biochemistry, and respiratory parameters. Systemic exposure to CN‐105 was independent of sex and did not appear to change following repeated administration. Full results on physiological testing of CN‐105 are found in Supplemental Material 1.

CN‐105 confers survival benefit and functional improvements {#acn3399-sec-0019}
-----------------------------------------------------------

CN‐105 administrated at 30‐min post reperfusion, compared to vehicle, significantly improved survival at 3 days (75% vs. 25%, *P* = 0.013) (Fig. [1](#acn3399-fig-0001){ref-type="fig"}). An additional dose of CN‐105 at 4.5 h after reperfusion maintained the survival benefit, but did not enhance it. Administration of CN‐105 also conferred functional improvement following ischemic injury as demonstrated by improved rotarod latency (*P* = 0.035) and hanging latency (*P* \< 0.001). The improvement was observed as early as the first day post injury and the benefit was maintained up to 7 days. No significant functional improvement was observed when CN‐105 was administered beyond 30 min post reperfusion (Fig. [2](#acn3399-fig-0002){ref-type="fig"}).

![CN‐105 confers survival benefit in ischemic stroke. Intravenous CN‐105 confers survival benefit at 3 days (A) when administered via a single dose at 30 min post reperfusion, and via 2 doses at 30 min and 4.5 h post reperfusion, utilizing the murine model of transient middle cerebral artery occlusion (tMCAO) of 30 min ischemic occlusion time. (\**P* \< 0.05 by log‐rank test compared to vehicle).](ACN3-4-246-g001){#acn3399-fig-0001}

![CN‐105 improves functional outcomes in ischemic stroke. (A) Improvement in rotarod latency when CN‐105 is administered 30 min post reperfusion, compared to vehicle. Improvement is observed from first day post stroke and increase over the subsequent 7 days. (B) Improvement in the 4‐limb wire hanging test latency when CN‐105 is administered 30 min post reperfusion, compared to vehicle. Improvement is observed from day 2 post‐stroke and maintained till day 7. (C) No improvement of rotarod timing observed when CN‐105 is administered 2 and 3 h post reperfusion. (D) Rotarod latency at day 7 for all treatment groups. (\**P* \< 0.05 and \*\*\**P* \< 0.001 by repeated measures ANOVA and \**P* \< 0.05 by independent *t*‐test, and error bars represent standard error of mean).](ACN3-4-246-g002){#acn3399-fig-0002}

CN‐105 reduces infarct volumes and contralateral microglial activation {#acn3399-sec-0020}
----------------------------------------------------------------------

CN‐105, when administered 30 min post reperfusion, demonstrated a significant reduction in infarct volume at 72 h post stroke. The reduction in infarct volume was observed in both our tMCAO models of 30 min (126.7 ± 9.9 mm^3^ vs. 79.2 ± 14.4 mm^3^, *P* = 0.023) and 15 min ischemic occlusion time (106.5 ± 8.8 mm^3^ vs. 70.8 ± 14.5 mm^3^, *P* = 0.048) (Fig. [3](#acn3399-fig-0003){ref-type="fig"}). This represents an approximate 38% and 34% reduction in infarct volume in the 30 min and 15 min models, respectively.

![Significant reduction in infarct volume at 72 h post stroke using 2% 2,3,5‐triphenyletrazolium chloride staining methods. Reduction was observed in both our murine transient middle cerebral artery occlusion models of (A) 30 min ischemic occlusion time and (B) 15 min ischemic occlusion time. Numbers indicate the number of mice that survived to 72 h in each experimental group. (C) Representative brain slices from the 30 min ischemic occlusion experiment demonstrating the reduction in infarct volume with CN‐105. (\**P* \< 0.05 by two‐tailed independent *t*‐test and error bars represent standard error of mean).](ACN3-4-246-g003){#acn3399-fig-0003}

We observed that the survival in the vehicle arm in this experiment with 30‐min ischemic occlusion‐time (6 of 12 mice) was better than the preceding mortality experiment (3 of 12 mice). However, the survival of the CN‐105 arm was the same for both experiments (9 of 12 mice). Moreover, a post hoc analysis of survival at 72‐h, by combining the survival data of both experiments and using a two‐tailed chi‐squared test, still demonstrated significant survival benefit (15/24 (62.5%) vs. 9/24 (37.5%), *P* = 0.0189), supporting the mortality benefit of CN‐105.

To assess the global protective effects from neuroinflammation by CN‐105 in focal ischemia, we quantified the amount of microglial activation in the contralateral uninjured hippocampus at 7 days post injury, following a 15‐min ischemic interval. Stereological analysis revealed significant increase in F4/80 immunopositive microglial cell density in tMCAO vehicle‐treated mice versus sham (9.8 ± 1.4 × 10^4^/mm^3^ vs. 3.5 ± 0.7 × 10^4^/mm^3^, *P* = 0.016). There was significant reduction in microglial cell density by CN‐105 compared to vehicle (6.8 ± 0.7 × 10^4^/mm^3^ vs. 9.8 ± 1.4 × 10^4^/mm^3^, *P* = 0.047) (Fig. [4](#acn3399-fig-0004){ref-type="fig"}).

![F4/80 immunocytochemical staining of microglia in contralateral hippocampus 7 days after ischemic stroke. (A) Microglial count density was significantly reduced by CN‐105, when administered 30 min post reperfusion, as compared to vehicle. Numbers indicate the number of mice that survived to 7 days in each experimental group. Representative images (4× magnification) of contralateral hippocampus demonstrating reduction in microglial cell density in hippocampal sections treated with vehicle (B) and CN‐105 (C). Microglial cells are stained brown by anti‐rat F4/80 antibody within the hippocampus. (\**P* \< 0.05 by two‐tailed independent *t*‐test and error bars represent standard error of mean).](ACN3-4-246-g004){#acn3399-fig-0004}

CN‐105 suppresses TNF‐*α* production in LPS‐stimulated microglial cells {#acn3399-sec-0021}
-----------------------------------------------------------------------

In cultures of C8‐B4 murine microglial cells, TNF‐*α* production was increased in response to LPS stimulation. There was significant suppression of microglial TNF‐*α* production in the presence of 1 *μ*M/mL concentration of CN‐105 versus LPS alone (121.5 ± 37 ng/mL vs. 245 ± 25 ng/mL, *P* = 0.0196) using 10 ng/ml LPS stimulation measured at 4 h. Although suppression of TNF‐*α* production was not significant at lower concentrations of CN‐105, the percentage of suppression of TNF‐*α* by CN‐105 is concentration‐dependent with 20%, 34% and 53% suppression observed with 0.1, 0.3 and 1 *μ*M/mL of CN‐105, respectively. CN‐105 was also able to suppress microglial TNF‐*α* secretion up to a concentration of 50 ng/mL of LPS stimulation (Fig. [5](#acn3399-fig-0005){ref-type="fig"}).

![CN‐105 induced suppression of microglial tumor necrosis factor alpha (TNF‐*α*) secretion. C8‐B4 microglial cells were incubated with LPS and subsequent TNF‐*α* production was quantified by enzyme‐linked immunosorbent assay (ELISA). (A) TNF‐*α* was measured at 4 h after incubation. (B) Percentage suppression of TNF‐*α* secretion using 10 ng/mL LPS measured at 4 h post incubation with 0.1, 0.3, and 1 *μ*M/mL of CN‐105 compared to LPS alone. (C) TNF‐*α* secretion at 10, 50, 100 ng/mL LPS with 1 *μ*mol/L of CN‐105. (\**P* \< 0.05 by two‐tailed independent *t*‐test and error bars represent standard error of mean) LPS, lipopolysaccharide.](ACN3-4-246-g005){#acn3399-fig-0005}

Phosphoproteomic signatures support neuroprotective effects of CN‐105 {#acn3399-sec-0022}
---------------------------------------------------------------------

To explore potential pathways by which CN‐105 exerted its neuroprotective effects, we performed a phosphoproteomic analysis of the ischemic brain. Protein phosphorylation is critical to cell signaling, in which the binding of ligand to an extracellular domain may modify multiple downstream cell functions.[51](#acn3399-bib-0051){ref-type="ref"}

CN‐105 affected phosphorylation of neuroinflammatory proteins in ischemic stroke. Seventy‐one unique phosphotyrosine sites were differentially changed between CN‐105 and vehicle, of which 6 were upregulated and 65 were downregulated by more than twofold. These 71 phosphotyrosine sites corresponded to 66 unique phosphoproteins. Notable phosphoproteins differentially changed by CN‐105 mediate cellular survival (Rho GTPase activating protein 1), immunity (tyrosine kinase Lyn), and BBB integrity (cyclophilin A) (Table [2](#acn3399-tbl-0002){ref-type="table-wrap"}). Biological processes altered by CN‐105 (Fig. [6](#acn3399-fig-0006){ref-type="fig"} and Table [S1](#acn3399-sup-0004){ref-type="supplementary-material"}), known signaling pathways, biological functions of each phosphoproteins, and results of enrichment specificity, data quality control, and outlier screening can be found in the supplementary material (Table [S2](#acn3399-sup-0005){ref-type="supplementary-material"}--[S3](#acn3399-sup-0006){ref-type="supplementary-material"} and Data [S2](#acn3399-sup-0002){ref-type="supplementary-material"}).

###### 

Statistically different phosphopeptides between CN‐105 and vehicle in ischemic stroke

  Protein Name                                                          Gene symbol and UniProtKB number   Modified peptide sequence[a](#acn3399-note-0003){ref-type="fn"} (phosphotyrosine position)   CN‐105 v vehicle fold change   *P* ‐value (two‐tailed *t*‐test)   Biological process of protein                                                                                                                                                                                                                                                      Function of specific phosphorylation site
  --------------------------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------------------------- ------------------------------ ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Upregulated Phosphopeptides**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Disks large‐associated protein 2                                      Dlgap2, Q8BJ42                     MH[**Y**]{.ul}SSHYDTR (169)                                                                  2.416                          0.040                              May play a role in the molecular organization of synapses and neuronal cell signaling.                                                                                                                                                                                             Unknown
  Golgi integral membrane protein 4                                     Golim4, Q8BXA1                     GRQEH[**Y**]{.ul}EEEEDEEDGAAVAEK (633)                                                       2.039                          0.037                              Plays a role in endosome to Golgi protein trafficking                                                                                                                                                                                                                              Controlled by leptin in mouse liver.
  Histone H4                                                            Hist1h4a, P62806                   KTVTAMDVV[**Y**]{.ul}ALK (88)                                                                2.473                          0.036                              Chromatin organization                                                                                                                                                                                                                                                             Unknown
  TVTAMDVV[**Y**]{.ul}ALK (88)                                          2.057                              0.026                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Insulin receptor substrate 2                                          Irs2, P81122                       SDD[**Y**]{.ul}MPMSPTSVSAPK (671)                                                            13.414                         0.048                              Transmembrane receptor protein tyrosine kinase signaling                                                                                                                                                                                                                           Insulin induce phosphorylation at Y671, which in turn activate PI3K/Akt/eNOS pathway in endothelial cells.
  Probable phospholipid‐transporting ATPase IA                          Atp8a1, P70704                     NTQWVHGIVV[**Y**]{.ul}TGHDTK (269)                                                           9.686                          0.020                              Anion transport, Catabolic process                                                                                                                                                                                                                                                 Unknown
  Sodium/potassium‐transporting ATPase subunit alpha‐1                  Atp1a1, Q8VDN2                     K[**Y**]{.ul}GTDLSR (55)                                                                     2.259                          0.036                              Homeostatic process, Catabolic process                                                                                                                                                                                                                                             Unknown
  **Downregulated Phosphopeptides**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  1‐phosphatidylinositol‐4,5‐bisphosphate phosphodiesterase gamma‐1     Plcg1, Q62077                      KLAEGSA[**Y**]{.ul}EEVPTSVMYSENDISNSIK (472)                                                 −3.211                         0.043                              Intracellular signal transduction via G‐protein‐coupled receptor signaling and Phospholipid metabolic process                                                                                                                                                                      Human analog controlled by ephrin_B1
  14‐3‐3 protein beta/alpha                                             Ywhab, Q9CQV8                      QTTVSNSQQA[**Y**]{.ul}QEAFEISKK (151)                                                        −2.391                         0.037                              Cell cycle                                                                                                                                                                                                                                                                         Unknown
  QTTVSNSQQA[**Y**]{.ul}QEAFEISK (151)                                  −2.434                             0.028                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Alpha‐enolase                                                         Eno1, P17182                       SGK[**Y**]{.ul}DLDFK (257)                                                                   −2.078                         0.035                              Glycolysis                                                                                                                                                                                                                                                                         Unknown
  Ankyrin‐2                                                             Ank2, Q8C8R3                       NG[**Y**]{.ul}TPLHIAAK (630)                                                                 −2.338                         0.010                              Protein localization and Intracellular protein transport                                                                                                                                                                                                                           Unknown
  QELEDNDK[**Y**]{.ul}QQFR (2113)                                       −6.332                             0.014                                                                                        Novel phosphorylation site                                                                                                                                                                                                                                                                                                                           
  Band 4.1‐like protein 1                                               Epb41l1, Q9Z2H5                    HLTQQDTRPAEQSLDMDDKD[**Y**]{.ul}SEADGLSER (68)                                               −3.678                         0.021                              May confer stability and plasticity to neuronal membrane                                                                                                                                                                                                                           Unknown
  Band 4.1‐like protein 3                                               Epb41l3, Q9WV92                    DSVSAAEVGTGQ[**Y**]{.ul}ATTK (479)                                                           −2.577                         0.024                              Inhibits cell proliferation and promotes apoptosis.                                                                                                                                                                                                                                Human isoform 2 (Y471) controlled by ephrin_B1.
  Calcium‐dependent secretion activator 2                               Cadps2, Q8BYR5                     T[**Y**]{.ul}DTLHR (1273)                                                                    −3.236                         0.012                              Exocytosis                                                                                                                                                                                                                                                                         Novel phosphorylation site
  Calmodulin‐regulated spectrin‐associated protein 2                    Camsap1 l1, Q8C1B1                 EEAAGAEDEKV[**Y**]{.ul}TDR (799)                                                             −2.566                         0.032                              Regulator of noncentrosomal microtubule dynamics and organization.                                                                                                                                                                                                                 Novel phosphorylation site
  Calmodulin‐regulated spectrin‐associated protein 3                    Kiaa1543, Q80VC9                   API[**Y**]{.ul}ISHPENPSK (520)                                                               −2.143                         0.033                              Regulator of noncentrosomal microtubule dynamics and organization.                                                                                                                                                                                                                 Unknown
  Casein kinase I isoform delta                                         Csnk1d, Q9DC28                     [**Y**]{.ul}ASINTHLGIEQSR (179)                                                              −2.342                         0.012                              Cellular component morphogenesis and endocytosis                                                                                                                                                                                                                                   Novel phosphorylation site
  CLIP‐associating protein 2                                            Clasp2, Q8BRT1                     DYNP[**Y**]{.ul}NYSDSISPFNK (1014)                                                           −2.972                         0.044                              Cell cycle.                                                                                                                                                                                                                                                                        Unknown
  CMRF35‐like molecule 8                                                Cd300a, Q6SJQ0                     AE[**Y**]{.ul}SEIQKPR (303)                                                                  −4.043                         0.048                              Intracellular protein transport and receptor‐mediated endocytosis                                                                                                                                                                                                                  Unknown
  Coronin‐1A                                                            Coro1a, O89053                     ADQC[**Y**]{.ul}EDVR (25)                                                                    −3.084                         0.038                              Cytoskeleton organization                                                                                                                                                                                                                                                          Unknown
  HVFGQPAKADQC[**Y**]{.ul}EDVR (25)                                     −5.976                             0.042                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Coronin‐2A                                                            Coro2a, Q8C0P5                     ENC[**Y**]{.ul}DSVPITR (26)                                                                  −2.633                         0.040                              Cytoskeleton organization                                                                                                                                                                                                                                                          Unknown
  Cytochrome c‐type heme lyase                                          Hccs, P53702                       AYD[**Y**]{.ul}VECPVTGAR (67)                                                                −5.111                         0.006                              Cell cycle and coenzyme metabolic process                                                                                                                                                                                                                                          Unknown
  Cytoplasmic dynein 1 heavy chain 1                                    Dync1h1, Q9JHU4                    AISKDHL[**Y**]{.ul}GTLDPNTR (2263)                                                           −4.501                         0.031                              Cellular component morphogenesis, Cell cycle, Cellular component movement, Intracellular protein transport                                                                                                                                                                         Unknown
  Dynamin‐1                                                             Dnm1, P39053                       RIEGSGDQIDT[**Y**]{.ul}ELSGGAR (354)                                                         −2.404                         0.044                              Cellular component morphogenesis, Intracellular protein transport, Endocytosis                                                                                                                                                                                                     Unknown
  IEGSGDQIDT[**Y**]{.ul}ELSGGAR (354)                                   −2.893                             0.045                                                                                                                                                                                                                                                                                                                                                                                                                                             
  EVDE[**Y**]{.ul}KNFRPDDPAR (314)                                      −3.247                             0.018                                                                                        Novel phosphorylation site                                                                                                                                                                                                                                                                                                                           
  LQSQLLSIEKEVDE[**Y**]{.ul}K (314)                                     −4.276                             0.038                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Dynamin‐1‐like protein                                                Dnm1l, Q8K1M6                      NKL[**Y**]{.ul}TDFDEIR (107)                                                                 −2.832                         0.047                              Cellular component morphogenesis, Intracellular protein transport, Endocytosis                                                                                                                                                                                                     Novel phosphorylation site
  EH domain‐containing protein 3                                        Ehd3, Q9QXY6                       ELVNNLAEI[**Y**]{.ul}GR (339)                                                                −3.179                         0.043                              Synaptic transmission, Intracellular protein transport, Endocytosis, Neurotransmitter secretion                                                                                                                                                                                    Unknown
  Eukaryotic translation initiation factor 4 gamma 1                    Eif4g1, Q6NZJ6                     KVE[**Y**]{.ul}TLGEESEAPGQR (1424)                                                           −2.610                         0.029                              Apoptosis                                                                                                                                                                                                                                                                          Unknown
  Glutaminase kidney isoform                                            Gls, D3Z7P3                        YAIAVNDLGTE[**Y**]{.ul}VHR (309)                                                             −5.463                         \<0.001                            Cellular amino acid biosynthetic catabolic process                                                                                                                                                                                                                                 Unknown
  Glutathione S‐transferase P 1                                         Gstp1, P19157                      YVTLIYTNYENGKND[**Y**]{.ul}VK (119)                                                          −2.652                         0.029                              Conjugation of reduced glutathione                                                                                                                                                                                                                                                 Novel phosphorylation site
  Heat shock protein 105                                                Hsph1, Q61699                      NAVEECV[**Y**]{.ul}EFRDK (644)                                                               −2.354                         0.043                              Protein complex assembly                                                                                                                                                                                                                                                           Unknown
  LysM and putative peptidoglycan‐binding domain‐containing protein 2   Lysmd2, Q9D7V2                     DEESP[**Y**]{.ul}AASLYHS (208)                                                               −3.571                         0.030                              Unknown                                                                                                                                                                                                                                                                            Unknown
  Microtubule‐associated protein 6                                      Map6, Q7TSJ2                       SL[**Y**]{.ul}SEPFKECPK (493)                                                                −3.469                         0.020                              Microtubule stabilization                                                                                                                                                                                                                                                          Unknown
  Myosin‐Va                                                             Myo5a, Q99104                      RTDSTHSSNESE[**Y**]{.ul}TFSSEFAETEDIAPR (1124)                                               −6.827                         0.041                              Cellular component morphogenesis, Intracellular signal transduction, Cell cycle, Cytokinesis, Muscle development, Intracellular protein transport, Muscle contraction, Sensory perception                                                                                          Unknown
  Myotrophin                                                            Mtpn, P62774                       D[**Y**]{.ul}VAKGEDVNR (21)                                                                  −3.285                         0.005                              Promotes dimerization of NF‐kappa‐B subunits and regulates NF‐kappa‐B transcription factor activity                                                                                                                                                                                Unknown
  Myotubularin‐related protein 5                                        Sbf1, Q6ZPE2                       RSTSTL[**Y**]{.ul}SQFQTAESENR (1751)                                                         −4.030                         0.005                              Intracellular protein transport, Phospholipid metabolic process                                                                                                                                                                                                                    Human analog controlled by Ephrin B1
  Neurochondrin                                                         Ncdn, Q9Z0E0                       SMIDDT[**Y**]{.ul}Q[**C**]{.ul}LTAVAGTPR (156)                                               −3.042                         0.044                              Signal transduction                                                                                                                                                                                                                                                                Novel phosphorylation site
  Peptidyl‐prolyl cis‐trans isomerase A                                 Ppia, P17742                       SI[**Y**]{.ul}GEKFEDENFILK (79)                                                              −2.432                         0.049                              Accelerate the folding of proteins                                                                                                                                                                                                                                                 Unknown
  Phosphatidylethanolamine‐binding protein 1                            Pebp1, P70296                      L[**Y**]{.ul}EQLSGK (181)                                                                    −2.263                         0.040                              Binds ATP, opioids and phosphatidylethanolamine                                                                                                                                                                                                                                    Regulated by Catsper1 in murine sperm
  Phosphoglycerate kinase 1                                             Pgk1, P09411                       LGDV[**Y**]{.ul}VNDAFGTAHR (161)                                                             −3.703                         0.011                              Glycolysis                                                                                                                                                                                                                                                                         Unknown
  Probable cationic amino acid transporter                              Slc7a14, Q8BXR1                    EQALHQST[**Y**]{.ul}QR (693)                                                                 −2.369                         0.040                              Amino acid transporter, Anion transport                                                                                                                                                                                                                                            Unknown
  Probable G‐protein‐coupled receptor 158                               Gpr158, Q8C419                     KL[**Y**]{.ul}AQLEIYKR (722)                                                                 −2.507                         0.003                              G‐protein‐coupled receptor signaling                                                                                                                                                                                                                                               Novel phosphorylation site
  Programmed cell death 6‐interacting protein                           Pdcd6ip, Q9WU78                    I[**Y**]{.ul}GGLTSK (608)                                                                    −4.124                         0.002                              Unknown orphan receptor.                                                                                                                                                                                                                                                           Novel phosphorylation site
  Protein arginine N‐methyltransferase 8                                Prmt8, Q6PAK3                      RGEEI[**Y**]{.ul}GTISMKPNAK (355)                                                            −2.181                         0.039                              Chromatin organization, Regulation of nucleobase‐containing compound metabolic process, Biosynthetic process, Transcription                                                                                                                                                        Unknown
  Protein EFR3 homolog B                                                Efr3b, Q6ZQ18                      KKEAP[**Y**]{.ul}MLPEDVFVEKPR (629)                                                          −2.364                         0.006                              Component of a complex required to localize phosphatidylinositol 4‐kinase (PI4K) to the plasma membrane                                                                                                                                                                            Novel phosphorylation site
  Protein FAM126B                                                       Fam126b, Q8C729                    [**Y**]{.ul}STISLQEDR (487)                                                                  −2.301                         0.026                              Mediates cellular transport and reorganization of the microtubule cytoskeleton                                                                                                                                                                                                     Unknown
  Protein kinase C and casein kinase substrate in neurons protein 1     Pacsin1, Q61644                    GPQ[**Y**]{.ul}GSLER (74)                                                                    −3.649                         0.012                              Cellular component morphogenesis, Cell differentiation, Nervous system development, Endocytosis                                                                                                                                                                                    Novel phosphorylation site
  Protein XRP2                                                          Rp2, Q9EPK2                        D[**Y**]{.ul}MFSGLKDETVGRLPGK (37)                                                           −3.700                         0.025                              Purine nucleobase metabolic process                                                                                                                                                                                                                                                Unknown
  Putative tyrosine‐protein phosphatase auxilin                         Dnajc6, Q80TZ3                     HLDHYTV[**Y**]{.ul}NLSPK (134)                                                               −2.616                         0.034                              Intracellular protein transport, Endocytosis                                                                                                                                                                                                                                       Novel phosphorylation site
  Receptor‐type tyrosine‐protein phosphatase‐like N                     Ptprn, Q60673                      LAALGPEGAHGDTTFE[**Y**]{.ul}QDLCR (628)                                                      −2.592                         0.031                              Plays a role in vesicle‐mediated secretory processes                                                                                                                                                                                                                               Unknown
  Regulator of G‐protein signaling 6                                    Rgs6, Q9Z2H2                       SV[**Y**]{.ul}GVTDETQSQSPVHIPSQPIRK (234)                                                    −3.918                         0.042                              Regulation of nucleobase‐containing compound metabolic process, Regulation of phosphate metabolic process, Catabolic process                                                                                                                                                       Novel phosphorylation site
  Rho GTPase‐activating protein 1                                       Arhgap1, Q5FWK3                    HQIVEVAGDDK[**Y**]{.ul}GR (81)                                                               −2.031                         0.043                              Regulation of nucleobase‐containing compound metabolic process, Regulation of phosphate metabolic process, Regulation of catalytic activity, Catabolic process.                                                                                                                    Unknown
  Rho GTPase‐activating protein 35                                      Arhgap35, Q91YM2                   KMQASPEYQD[**Y**]{.ul}VYLEGTQK (308)                                                         −3.163                         0.035                              Regulation of nucleobase‐containing compound metabolic process, Regulation of phosphate metabolic process, Regulation of catalytic activity, Catabolic process                                                                                                                     Growth factors induce phosphorylation of thyrosine at position 308, which disrupts its ability to bind with General Transcription Factor II‐I.
  SH3 and cysteine‐rich domain‐containing protein 2                     Stac2, Q8R1B0                      ESPPTGTSGKVDPV[**Y**]{.ul}ETLR (205)                                                         −2.054                         0.044                              Unknown                                                                                                                                                                                                                                                                            Unknown
  SH3 and PX domain‐containing protein 2B                               Sh3pxd2b, A2AAY5                   TEPAQSEDHVDI[**Y**]{.ul}NLR (661)                                                            −3.128                         0.040                              Intracellular signal transduction                                                                                                                                                                                                                                                  Unknown
  SLIT‐ROBO Rho GTPase‐activating protein 3                             Srgap3, Q812A2                     NDLQSPTEHISD[**Y**]{.ul}GFGGVMGR (845)                                                       −2.312                         0.024                              Regulation of nucleobase‐containing compound metabolic process, Regulation of phosphate metabolic process, Cellular component movement, Locomotion, Catabolic process                                                                                                              Unknown
  Src substrate cortactin                                               Cttn, Q60598                       NASTFEEVVQVPSA[**Y**]{.ul}QK (334)                                                           −3.605                         0.030                              Cellular component morphogenesis                                                                                                                                                                                                                                                   Phosphorylation is by proto‐oncogene tyrosine‐protein kinase Src and dephosphorylation is by protein tyrosine phosphophatase 1B.
  Synaptic vesicle glycoprotein 2B                                      Sv2b, Q8BG39                       YRDN[**Y**]{.ul}EGYAPSDGYYR (10)                                                             −2.635                         0.004                              Synaptic transmission, Neurotransmitter secretion                                                                                                                                                                                                                                  Unknown
  DN[**Y**]{.ul}EGYAPSDGYYR (10)                                        −3.735                             0.016                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Synaptogyrin‐3                                                        Syngr3, Q8R191                     G[**Y**]{.ul}QVPAY (224)                                                                     −3.971                         0.026                              Positive regulation of dopamine transporter activity                                                                                                                                                                                                                               Novel phosphorylation site
  Syntaxin‐binding protein 1                                            Stxbp1, O08599                     ERISEQT[**Y**]{.ul}QLSR (473)                                                                −2.563                         0.035                              Lysosomal transport, Intracellular protein transport, Synaptic vesicle exocytosis, Neurotransmitter secretion                                                                                                                                                                      Unknown
  ISEQT[**Y**]{.ul}QLSR (473)                                           −2.843                             0.015                                                                                                                                                                                                                                                                                                                                                                                                                                             
  [**Y**]{.ul}STHLHLAEDCMK (344)                                        −2.920                             0.019                                                                                        Novel phosphorylation site                                                                                                                                                                                                                                                                                                                           
  H[**Y**]{.ul}QGTVDKLCR (358)                                          −3.161                             0.025                                                                                        Novel phosphorylation site                                                                                                                                                                                                                                                                                                                           
  Thioredoxin reductase 1, cytoplasmic                                  Txnrd1, Q9JMH6                     VVYENA[**Y**]{.ul}GR (245)                                                                   −2.016                         0.032                              Respiratory electron transport chain                                                                                                                                                                                                                                               Phosphorylation is by proto‐oncogene tyrosine‐protein kinase Src. Phosphorylation of human analog (tyrosine 281) reduced by ZAP70 and upregulated in neuroblastoma.
  Triosephosphate isomerase                                             Tpi1, P17751                       II[**Y**]{.ul}GGSVTGATCK (259)                                                               −2.893                         0.029                              Glycolysis and gluconeogensis                                                                                                                                                                                                                                                      Unknown
  Tubulin polymerization‐promoting protein                              Tppp, Q7TQD2                       VDLVDESG[**Y**]{.ul}VPGYK (200)                                                              −3.438                         0.008                              Microtubule functions                                                                                                                                                                                                                                                              Unknown
  Type I inositol 3,4‐bisphosphate 4‐phosphatase                        Inpp4a, Q9EPW0                     VQDDGGSDQN[**Y**]{.ul}DVVTIGAPAAHCQGFK (355)                                                 −2.552                         0.013                              Regulation of megakaryocyte and fibroblast proliferation                                                                                                                                                                                                                           Unknown
  HYRPPEGT[**Y**]{.ul}GKVET (934)                                       −3.111                             0.031                                                                                        Unknown                                                                                                                                                                                                                                                                                                                                              
  Tyrosine‐protein kinase                                               Lyn, P25911                        VIEDNE[**Y**]{.ul}TAR (397)                                                                  −2.289                         0.015                              Cell adhesion, Transmembrane receptor protein tyrosine kinase signaling, Cell proliferation, Cellular component movement, Cell differentiation, Apoptosis, Hemopoiesis, Nervous system development, Immune system response, Exocytosis, Locomotion, Coagulation, Stress response   Phosphorylation of tyrosine in at tyrosine 397, located within the activation loop, is required for its kinase activity. Lyn is activated by B‐cell receptor and inhibited by CD45.
  UPF0554 protein C2orf43 homolog                                       Ldah, Q8BVA5                       IEDV[**Y**]{.ul}GLNGQIEHK (111)                                                              −2.475                         0.015                              Serine lipid hydrolase associated with lipid droplets                                                                                                                                                                                                                              Novel phosphorylation site
  Vesicular inhibitory amino acid transporter                           Slc32a1, O35633                    SEGEPCGDEGAEAPVEGDIH[**Y**]{.ul}QR (Y85)                                                     −2.321                         0.020                              Amino acid transporter, Anion transport                                                                                                                                                                                                                                            Unknown
  Wolframin                                                             Wfs1, P56695                       N[**Y**]{.ul}IALDDFVELTKK (242)                                                              −7.251                         0.045                              Regulation of cellular Ca2 + homeostasis                                                                                                                                                                                                                                           Unknown

Underlined amino acid represents phosphorylated tyrosine and numbers in brackets indicate the phosphotyrosine position.
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![Main biological processes of differentially expressed phosphoproteins by CN‐105 in ischemic stroke. Sixty‐six phosphoproteins were differentially expressed between CN‐105 and vehicle in ischemic stroke. Majority of the biological functions of these phosphoproteins were involved in cell survival and signaling.](ACN3-4-246-g006){#acn3399-fig-0006}

Discussion {#acn3399-sec-0023}
==========

Our study has demonstrated that CN‐105, an apoE‐mimetic pentapeptide, reduces mortality, infarct volume, microgliosis, and improves long‐term functional outcome in a murine reperfusion model of ischemic stroke. We have previously demonstrated that larger peptides derived from the apoE receptor‐binding region (apoE133‐149) retain the neuroprotective and anti‐inflammatory properties[8](#acn3399-bib-0008){ref-type="ref"}, [17](#acn3399-bib-0017){ref-type="ref"}, [30](#acn3399-bib-0030){ref-type="ref"}, [52](#acn3399-bib-0052){ref-type="ref"}, [53](#acn3399-bib-0053){ref-type="ref"} of the apoE holoprotein. However, these peptides were limited by their relatively larger size, resulting in lower CNS penetration and higher cost of production. CN‐105, our current apoE‐mimetic pentapeptide, retains the beneficial neuroprotective effect in ischemic stroke observed in other apoE‐mimetic peptides[31](#acn3399-bib-0031){ref-type="ref"}, [32](#acn3399-bib-0032){ref-type="ref"} and possesses increased CNS penetration and potency.[35](#acn3399-bib-0035){ref-type="ref"}

We demonstrated that CN‐105 downregulates microglial activation in ischemic stroke and suppress TNF‐*α* secretion from C8‐B4 microglial cells. These immune‐modulatory effects on microglial by CN‐105 are consistent with apoE[15](#acn3399-bib-0015){ref-type="ref"}, [16](#acn3399-bib-0016){ref-type="ref"}, [17](#acn3399-bib-0017){ref-type="ref"}, [54](#acn3399-bib-0054){ref-type="ref"} and other apoE‐mimetic peptides.[17](#acn3399-bib-0017){ref-type="ref"}, [34](#acn3399-bib-0034){ref-type="ref"} LRP1, a cell surface receptor, has been shown to bind apoE[55](#acn3399-bib-0055){ref-type="ref"} and other apoE‐mimetic peptides.[29](#acn3399-bib-0029){ref-type="ref"}, [56](#acn3399-bib-0056){ref-type="ref"} The function of this interaction between apoE and LRP1, has been associated with suppression of neuroinflammation.[57](#acn3399-bib-0057){ref-type="ref"} Microglial cells, which expresses LRP1, are resident macrophages within the CNS that become activated in pathological situations, including cerebral ischemia.[58](#acn3399-bib-0058){ref-type="ref"} Microglial activation results in oxidative stress and the release of inflammatory mediators, contributing to BBB breakdown, secondary neuronal injury, and development of cerebral edema.[59](#acn3399-bib-0059){ref-type="ref"} There is evidence that apoE‐mimetic peptides reduce these inflammatory responses in microglial cells, via LRP1, through the c‐Jun N‐terminal kinases (JNKs) pathway.[60](#acn3399-bib-0060){ref-type="ref"}, [61](#acn3399-bib-0061){ref-type="ref"} JNKs are stress‐activated protein kinases that mediate the activation of microglia.[62](#acn3399-bib-0062){ref-type="ref"} External cellular stress, such as ischemia, induces a complex system of upstream signals, which in turn activates JNKs and results in expression of transcription factors, such as c‐Jun or c‐Fos, that participate in apoptosis and many cell death paradigms.[62](#acn3399-bib-0062){ref-type="ref"} Our early phosphoproteomic results support the hypothesis that CN‐105 mediates the downregulation of JNK pathway, through the identification of the differentially phosphorylated Rho GTPase‐activating protein 1 (Arghap1). Arghap1 serves as a upstream molecular switch which converts various stress‐induced proteins into an inactive state[63](#acn3399-bib-0063){ref-type="ref"} (Fig. [7](#acn3399-fig-0007){ref-type="fig"}). These inactivated proteins are then unable to transmit signals to activate JNKs downstream.[64](#acn3399-bib-0064){ref-type="ref"}

![Rho GTPase‐activating protein 1 (Arghap1) downregulates c‐JNKs pathway through inactivation of stress‐induced proteins. External cellular stress induces activation of Ras‐Related C3 Botulinum Toxin Substrate (Rac) and Cell Division Cycle‐42 (CDC42). This triggers the sequential activation of mitogen‐activated protein kinase kinase kinases (MAPKKKs) and mitogen‐activated protein kinase kinases 4/7, resulting in JNKs activation. Arghap1 accelerate the intrinsic GTPase activity of Rac and CDC42 to return it to the inactive GDP‐bound conformation, resulting in downregulation of subsequent pathways. JNKs, Jun N‐terminal kinases.](ACN3-4-246-g007){#acn3399-fig-0007}

Our study revealed a novel finding of increased microglial activation in the uninjured contralateral hippocampus after experimental ischemic stroke. Although the blood supply is not interrupted, it has been previously reported that the "healthy" contralateral hemisphere of an ischemic brain is associated with radiographic changes[65](#acn3399-bib-0065){ref-type="ref"} in the immediate poststroke period. Secretion of inflammatory mediators and trophic factors by non‐neuronal cells[66](#acn3399-bib-0066){ref-type="ref"} has been implicated. Our current finding of elevated microglial cell density in the contralateral hippocampus suggest that global and potentially detrimental inflammatory changes exist throughout the brain following focal ischemia. Remote downregulation of microglial activation in the contralateral uninjured hippocampus by CN‐105 suggests its anti‐inflammatory benefit extends beyond the effect of reducing the ipsilateral infarct volume.

A possible mechanism by which CN‐105 exerts its anti‐inflammatory and neuroprotective effect may be through the preservation of the BBB. After ischemic stroke, BBB disruption occurs and persists for days. ApoE appears to protect cerebrovascular integrity in acute brain injury through maintenance of the BBB, as demonstrated in apoE‐deficient mice, which was associated with an increase in disruption of BBB after injury.[67](#acn3399-bib-0067){ref-type="ref"}, [68](#acn3399-bib-0068){ref-type="ref"}, [69](#acn3399-bib-0069){ref-type="ref"} More recently, it has been found that apoE stabilizes BBB through suppression of cyclophilin A (Peptidylprolyl cis‐trans isomerase A or CypA) in an isoform‐specific manner via interaction with LRP1.[57](#acn3399-bib-0057){ref-type="ref"} We observed, through our phosphoproteomic study, that CN‐105 downregulated phosphorylation of CypA in ischemic stroke. This is consistent with the hypothesis that CN‐105 downregulates CypA and results in improved BBB integrity following ischemic stroke. Additionally, the phosphorylation site identified at tyrosine 79 of CypA in our data possibly points toward a critical signaling mechanism between CypA and either the upstream LRP1 receptor or downstream nuclear‐factor‐keppa‐beta transcription factor[61](#acn3399-bib-0061){ref-type="ref"} and deserves further investigation. CypA has also been additionally implicated in posthypoxic apoptosis via apoptosis‐inducing factor,[70](#acn3399-bib-0070){ref-type="ref"} suggesting that downregulation of CypA by CN‐105 may confer other neuroprotective effects.

Reduction in early mortality (24--72 h) after ischemic stroke was observed in our study with CN‐105. Early mortality in acute ischemic stroke is associated with initial clinical stroke severity, the size of the infarct and subsequent cerebral edema.[71](#acn3399-bib-0071){ref-type="ref"}, [72](#acn3399-bib-0072){ref-type="ref"}, [73](#acn3399-bib-0073){ref-type="ref"} Mechanism which CN‐105 reduced early mortality were likely through decreasing overall infarct size, as observed in our study, and also through decreasing cerebral edema by maintaining BBB integrity. Inflammation begins within hours in the postischemic brain,[74](#acn3399-bib-0074){ref-type="ref"}, [75](#acn3399-bib-0075){ref-type="ref"} resulting in activation of microglial and secretion of inflammatory cytokines within 24 h of infarction.[76](#acn3399-bib-0076){ref-type="ref"} These inflammatory cytokines contributes to cerebral edema through disruption of BBB integrity.[77](#acn3399-bib-0077){ref-type="ref"} Additionally, through the downregulation of phophorylation of CypA, as demonstrated in our phosphoproteomic results, CN‐105 also maintains BBB integrity, reducing cerebral edema after injury. All these factors contributes to the reduction in early mortality.

Other differentially phosphorylated proteins may also provide clue toward CN‐105′s mechanism of action. For example, CN‐105 may suppress microglial activation through the deactivation of Lyn. Lyn belongs to the Src family of tyrosine kinases predominantly expressed in granulocytes[78](#acn3399-bib-0078){ref-type="ref"} and involved in early B‐cell signaling pathway.[79](#acn3399-bib-0079){ref-type="ref"} Inhibition of Lyn showed suppression of microglial activation in an Alzheimer\'s disease model.[80](#acn3399-bib-0080){ref-type="ref"} Phosphorylation at tyrosine 397 (p‐Tyr397‐Lyn) is required for Lyn to perform its functional kinase activity[81](#acn3399-bib-0081){ref-type="ref"} to effect downstream proinflammatory pathways.[79](#acn3399-bib-0079){ref-type="ref"} Hence our observation of downregulation of p‐Tyr397‐Lyn suggests a possible mechanism by which CN‐105 reduces microglial activation. Moreover, Lyn activation has been implicated in degranulation of mast cells[82](#acn3399-bib-0082){ref-type="ref"} releasing histamine, consistent with our previous observation that apoE‐deficient mice possess elevated histamine after acute brain injury.[83](#acn3399-bib-0083){ref-type="ref"}

Our study was limited by the inability to demonstrate improved functional outcome when CN‐105 was administered at 0.1 mg/kg beyond a latency of 30 min from ischemia. Although the protective effect of CN‐105 appears to be time‐dependent, our study was focused on delineating the early mechanistic effects of CN‐105 in ischemic stroke, and did not test the effects of higher drug dosage or multiple dosing, which have increased efficacy in prior studies.[32](#acn3399-bib-0032){ref-type="ref"} Since CN‐105 does not include the polymorphic region of the apoE holoprotein, the differential effects of ApoE isoforms were not investigated. An inherent limitation of the phosphoproteomic approach was the use of a twofold cutoff to determine significance between treatment groups. This could have excluded certain important phosphopeptides, with small initial changes, that may be associated with amplified downstream neuroprotective effects. The efficacy of CN‐105 would also have been further enhanced if evaluated in different models of ischemic stroke and female mice. Additionally, to elucidate if CN‐105 works definitively through LRP1, antagonism or genetic knock‐out models of LRP1 will be needed.

In summary, we demonstrate that intravenous administration of CN‐105 conferred durable sensorimotor functional improvements, reduced mortality, histological inflammation, and inflammatory phosphoproteomic signals following cerebral ischemia. In vitro application of CN‐105 also reduced microglial activation. With safety already demonstrated in a clinical trial, CN‐105 may be an attractive candidate for further clinical evaluation in ischemic stroke.
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